Welcome to our dedicated page for NRIFF news (Ticker: NRIFF), a resource for investors and traders seeking the latest updates and insights on NRIFF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRIFF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRIFF's position in the market.
Miravo Healthcare has signed an exclusive License Agreement with SK Chemicals to commercialize Suvexx in South Korea. Effective July 29, 2021, the deal includes up to EUR 1.1 million in payments and potential royalties on sales. The South Korean migraine market was valued at over US$20 million in 2020. Suvexx is expected to gain 6 years of marketing exclusivity upon regulatory approval, with a launch anticipated in 2023. SK Chemicals, a major player in Korea, generated US$1.0 billion in sales in 2020.
